About two and a half years before they sealed a $3.3 billion deal, Bain Capital and its life sciences team started courting ...

HiveBio's partners on the new accelerator include Thomas Jefferson University, Drexel University, Robin Hood Ventures, ...

Through this platform, Carlyle will help Roop and Highway leverage operating synergies, create capabilities and capacities ...

We recently published a list of 11 AI News and Ratings on Investors’ Radar. In this article, we are going to take a look at ...

We recently published a list of 11 AI News and Ratings on Investors’ Radar. In this article, we are going to take a look at ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Fintel reports that on February 12, 2025, Keybanc initiated coverage of Rapid Micro Biosystems (NasdaqCM:RPID) with a ...

Bain Capital, Advent International and EQT AB are among the private equity firms competing to acquire Japanese cybersecurity ...

Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...